AstraZeneca aims to redefine breast cancer care with new data across the treatment spectrum at SABCS 2022
Data will show clinical opportunity in HR-positive advanced breast cancer for potential first-in-class AKT inhibitor capivasertib and next-generation oral SERD camizestrant. Enhertu data will reinforce potential to set new standards in HER2-targetable disease. Data for antibody drug conjugate datopotamab deruxtecan will demonstrate potential in HR-positive and triple-negative breast cancer.AstraZeneca will present new data advancing its ambition to redefine care at the 2022 San Antonio Breast Cancer Symposium (SABCS), 6-10 December 2022. Twelve AstraZeneca medicines and potential